在患有轻链心脏粉症的患者中,基线和可溶性ST2变化的预后值
Anran Xin1, Xinqing Li1, Yan Huang1
1Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing China.
Journal of the American Heart Association
|December 3, 2025
概括
瘤发生性-2 (sST2) 的升高基线可溶性抑制及其30天的增加预测轻链心肌粉症患者的死亡率. 这些标志物为管理AL-CA.提供了关键的预后见解.
科学领域:
- 心脏病学 心脏病学
- 生物标志物 生物标志物
- 氨基粉症研究研究
背景情况:
- 轻链心脏粉症 (AL-CA) 溶性抑制瘤发生性-2 (sST2) 的动态变化的预后价值尚未得到充分确立.
- 这项研究调查了AL-CA患者的基线sST2水平及其30天变化 (ΔsST2) 的预后意义.
研究的目的:
- 确定基线sST2水平和短期sST2变化是否预测AL-CA患者的全因死亡率.
- 通过生存分析评估这些sST2参数的独立预后值.
主要方法:
- 一组172名AL-CA患者的基线sST2测量; 一组70名患者在30天后进行了重复测量.
- 所有原因的死亡率是主要的结局. 使用Kaplan-Meier和Cox回归模型评估了基线sST2和ΔsST2的预测值.
- 限制立方线分析了变量与死亡率之间的关系.
主要成果:
- 较高的基线sST2 (>35 ng/mL) 与增加的死亡风险有关 (aHR,1.82).
- 在基线sST2和死亡率之间观察到非线性关联.
- 30天 sST2 升高 (ΔsST2 >18 ng/mL) 独立预测更糟糕的预后 (aHR,9.87).
结论:
- 升高的基线sST2水平与AL-CA的预后不佳有关.
- 短期上升的sST2水平也预测AL-CA患者的预后会更差.
- sST2动态为AL-CA管理提供了有价值的预后信息.
相关概念视频
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
763
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
763
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
521
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
521
01:30Acute Coronary Syndrome III: Diagnostic Studies
199
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
199
01:23Mitral Stenosis II: Clinical features and Diagnostic Tests
196
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
196